Literature DB >> 28765473

Faecal microbiota composition associates with abdominal pain in the general population.

Fatemeh Hadizadeh1,2, Ferdinando Bonfiglio1,3, Meriem Belheouane4,5, Marie Vallier4,5, Sascha Sauer6, Corinna Bang7, Luis Bujanda3,8, Anna Andreasson9,10, Lars Agreus9, Lars Engstrand11,12, Nicholas J Talley9,13,14,15, Joseph Rafter1, John F Baines4,5, Susanna Walter16, Andre Franke7, Mauro D'Amato3,17,18.   

Abstract

Entities:  

Keywords:  abdominal pain; colonic microflora

Mesh:

Year:  2017        PMID: 28765473      PMCID: PMC6058062          DOI: 10.1136/gutjnl-2017-314792

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
We read with great interest the recent communication by Simrén et al,1 reporting a correlation between visceral hypersensitivity and GI symptom severity in functional GI disorders (FGID). Previously, it has been shown that visceral hypersensitivity can be modulated or even induced in animal models, by altering the composition of their gut microbiota with antibiotics or faecal transplantation from IBS donors.2 3 Hence, while a direct link between gut microbiota composition and visceral pain may need to be conclusively established, this holds great potential for translational exploitation in the treatment of IBS and other FGID. Thus far, the potential association between microbiota and abdominal pain in humans has only been investigated in one study that included 15 individuals.4 For this purpose, we studied 159 individuals (average age 59.1, 39.6% men) from the Swedish Population-based Colonoscopy (PopCol) cohort, previously described and with faecal microbiota 16S sequencing data and daily recordings of abdominal pain (number of episodes, duration and intensity) collected over the same period (7.41±7.91 days).5–7 Among these, 52 individuals (assigned to the case group) reported at least one episode of light, moderate or intense pain (respective scores 1, 2 and 3), while the other 107 (controls) never reported pain. On average, those with pain experienced it 0.30 times per day (range 0.07–1.57), for 2.46 hours each time (range 0.37–9) and on a light-moderate intensity level of 1.39 per episode (range 1–2.1). When compared, both at the level of genus and species-level operational taxonomic units (OTU), β-diversity measures of faecal microbiota from cases and controls significantly differed (figure 1). In addition, significant correlations with microbiota β-diversity were detected for pain indices of frequency, duration and intensity (figure 1). Classifying individuals according to their microbiota profiles clustered into enterotypes (http://enterotyping.embl.de) resulted in three groups, respectively, enriched for unclassified Ruminococcaceae, Prevotella and Bacteroides. As shown in figure 2, a χ2 analysis revealed their distribution to be significantly different in cases and controls (p=0.039), and the Prevotella-predominant enterotype was underrepresented in the pain group (21% vs 41% in controls). When taxa previously associated with abdominal symptoms in animal models and clinical studies (Bacteroides, unclassified Ruminococcaceae, Butyricicoccus, Prevotella, Faecalibacterium, Streptococcus, Bifidobacterium, Blautia, Akkermansia, Lactobacillus, Alistipes and Enterobacter) were compared with a Wilcoxon rank-sum test for their abundance in the pain and control groups, Benjamini-Hochberg corrected significant differences were observed for Prevotella (decreased in cases, p=0.038), Blautia (increased in cases, p=0.045), Streptococcus (increased in cases, p=0.038) and Lactobacillus (increased in cases, p=0.038). In particular, in an indicator value analysis on genus level, Prevotella could significantly predict the absence of abdominal pain (corrected p=0.016, association statistics=0.76 using the multipatt function of the R package indicspecies). Similar results were obtained when testing correlations with pain frequency, duration and intensity and after removal of individuals (n=18) whose questionnaire data were compatible with a diagnosis of IBS according to Rome III criteria (not shown).
Figure 1

Faecal microbiota β-diversity associates with abdominal pain. Top: Heat map of Spearman correlation between pain indices and faecal microbiota β-diversity, based on principal coordinate analysis applied to Bray-Curtis and Jaccard matrices at the level of genera (Genera) and operational taxonomic units with 97% sequence similarity (OTU 97%). The first three principal coordinates (PC) are reported (PC1, PC2 and PC3) and significant correlations (false discovery rate < 0.1) are highlighted by a black frame. Bottom: Box plots of PC scores in cases and controls, where significant differences (corrected p value<0.05) are highlighted with *.

Figure 2

Faecal microbiota enterotype distribution differs in individuals with abdominal pain compared with controls. Principal component analysis (left) and relative distribution (right) of enterotypes according to the presence (case) or absence (control) of abdominal pain. Participants were classified into three enterotypes primarily characterised by unclassified Ruminococcaceae, Prevotella or Bacteroides. *p<0.05.

Faecal microbiota β-diversity associates with abdominal pain. Top: Heat map of Spearman correlation between pain indices and faecal microbiota β-diversity, based on principal coordinate analysis applied to Bray-Curtis and Jaccard matrices at the level of genera (Genera) and operational taxonomic units with 97% sequence similarity (OTU 97%). The first three principal coordinates (PC) are reported (PC1, PC2 and PC3) and significant correlations (false discovery rate < 0.1) are highlighted by a black frame. Bottom: Box plots of PC scores in cases and controls, where significant differences (corrected p value<0.05) are highlighted with *. Faecal microbiota enterotype distribution differs in individuals with abdominal pain compared with controls. Principal component analysis (left) and relative distribution (right) of enterotypes according to the presence (case) or absence (control) of abdominal pain. Participants were classified into three enterotypes primarily characterised by unclassified Ruminococcaceae, Prevotella or Bacteroides. *p<0.05. Our results provide novel evidence linking faecal microbiota composition to the occurrence of abdominal pain and its frequency, duration and intensity in the general population. The negative association of Prevotella with pain parallels observations previously made in IBS studies where the Prevotella-predominant enterotype was shown to be less common among patients.8 The information we report at the general population level may contribute to translational opportunities for the identification and treatment of individuals at risk of IBS and other FGIDs and warrants further studies in independent populations.
  8 in total

1.  The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota.

Authors:  L Crouzet; E Gaultier; C Del'Homme; C Cartier; E Delmas; M Dapoigny; J Fioramonti; A Bernalier-Donadille
Journal:  Neurogastroenterol Motil       Date:  2013-02-25       Impact factor: 3.598

2.  Stool frequency is associated with gut microbiota composition.

Authors:  Fatemeh Hadizadeh; Susanna Walter; Meriem Belheouane; Ferdinando Bonfiglio; Femke-Anouska Heinsen; Anna Andreasson; Lars Agreus; Lars Engstrand; John F Baines; Joseph Rafter; Andre Franke; Mauro D'Amato
Journal:  Gut       Date:  2016-04-28       Impact factor: 23.059

3.  A randomly selected population sample undergoing colonoscopy: prevalence of the irritable bowel syndrome and the impact of selection factors.

Authors:  Lars Kjellström; Herdis Molinder; Lars Agréus; Henry Nyhlin; Nicholas J Talley; Anna Andreasson
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-03       Impact factor: 2.566

4.  Assessment of normal bowel habits in the general adult population: the Popcol study.

Authors:  Susanna A Walter; Lars Kjellström; Henry Nyhlin; Nicholas J Talley; Lars Agréus
Journal:  Scand J Gastroenterol       Date:  2010-05       Impact factor: 2.423

5.  Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts.

Authors:  Magnus Simrén; Hans Törnblom; Olafur S Palsson; Miranda A L van Tilburg; Lukas Van Oudenhove; Jan Tack; William E Whitehead
Journal:  Gut       Date:  2017-01-19       Impact factor: 23.059

6.  Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome.

Authors:  Julien Tap; Muriel Derrien; Hans Törnblom; Rémi Brazeilles; Stéphanie Cools-Portier; Joël Doré; Stine Störsrud; Boris Le Nevé; Lena Öhman; Magnus Simrén
Journal:  Gastroenterology       Date:  2016-10-07       Impact factor: 22.682

7.  Stress and antibiotics alter luminal and wall-adhered microbiota and enhance the local expression of visceral sensory-related systems in mice.

Authors:  M Aguilera; P Vergara; V Martínez
Journal:  Neurogastroenterol Motil       Date:  2013-05-27       Impact factor: 3.598

8.  Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms.

Authors:  Jonna Jalanka-Tuovinen; Anne Salonen; Janne Nikkilä; Outi Immonen; Riina Kekkonen; Leo Lahti; Airi Palva; Willem M de Vos
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

  8 in total
  11 in total

Review 1.  Initiatives for a Healthy Stomach.

Authors:  Chun-Ying Wu
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 2.  Immune activation in irritable bowel syndrome: what is the evidence?

Authors:  Javier Aguilera-Lizarraga; Hind Hussein; Guy E Boeckxstaens
Journal:  Nat Rev Immunol       Date:  2022-03-16       Impact factor: 53.106

Review 3.  MicroRNA and Gut Microbiota: Tiny but Mighty-Novel Insights into Their Cross-talk in Inflammatory Bowel Disease Pathogenesis and Therapeutics.

Authors:  Maite Casado-Bedmar; Emilie Viennois
Journal:  J Crohns Colitis       Date:  2022-07-14       Impact factor: 10.020

4.  The Role of Bacteria and Its Derived Metabolites in Chronic Pain and Depression: Recent Findings and Research Progress.

Authors:  Shan Li; Dongyu Hua; Qiaoyan Wang; Ling Yang; Xinlei Wang; Ailin Luo; Chun Yang
Journal:  Int J Neuropsychopharmacol       Date:  2020-03-10       Impact factor: 5.176

5.  No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population.

Authors:  Luisa W Hugerth; Anna Andreasson; Nicholas J Talley; Anna M Forsberg; Lars Kjellström; Peter Thelin Schmidt; Lars Agreus; Lars Engstrand
Journal:  Gut       Date:  2019-10-10       Impact factor: 23.059

Review 6.  Dietary Fat Effect on the Gut Microbiome, and Its Role in the Modulation of Gastrointestinal Disorders in Children with Autism Spectrum Disorder.

Authors:  Monia Kittana; Asma Ahmadani; Farah Al Marzooq; Amita Attlee
Journal:  Nutrients       Date:  2021-10-27       Impact factor: 5.717

7.  Visceral sensitivity modulation by faecal microbiota transplantation: the active role of gut bacteria in pain persistence.

Authors:  Elena Lucarini; Vincenzo Di Pilato; Carmen Parisio; Laura Micheli; Alessandra Toti; Alessandra Pacini; Gianluca Bartolucci; Simone Baldi; Elena Niccolai; Amedeo Amedei; Gian Maria Rossolini; Claudio Nicoletti; John F Cryan; Siobhain M O'Mahony; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Pain       Date:  2022-05-01       Impact factor: 6.961

8.  Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?

Authors:  Liyuan Xiang; Xiao Ding; Qianqian Li; Xia Wu; Min Dai; Chuyan Long; Zhi He; Bota Cui; Faming Zhang
Journal:  Microb Biotechnol       Date:  2020-01-20       Impact factor: 5.813

9.  Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.

Authors:  Anthony Lembo; Satish S C Rao; Zeev Heimanson; Mark Pimentel
Journal:  Clin Transl Gastroenterol       Date:  2020-03       Impact factor: 4.396

10.  Efficacy of prebiotics and probiotics for functional dyspepsia: A systematic review and meta-analysis.

Authors:  Jiaqi Zhang; Hao Meng Wu; Xue Wang; Jingyi Xie; Xia Li; Jinxin Ma; Fengyun Wang; Xudong Tang
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.